Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 5/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1093557 | 1.00 | CRBN (0.47) | CRBN | |
| SCHEMBL1093267 | 0.83 | CRBN (0.47) | CRBN | |
| SCHEMBL29809267 | 0.79 | CRBN (0.57) | CRBN | |
| SCHEMBL22159524 | 0.79 | CRBN (0.57) | CRBN | |
| SCHEMBL1094270 | 0.76 | CRBN (0.49) | CRBN | |
| SCHEMBL13925892 | 0.76 | CRBN (0.49) | CRBN | |
| SCHEMBL1094273 | 0.76 | CRBN (0.49) | CRBN | |
| Hydrochloric Acid SCHEMBL1092629 | 0.75 | CRBN (0.48) | CRBN | |
| SCHEMBL1092657 | 0.74 | — | — | |
| SCHEMBL1092659 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153652-B2 | Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2012-04-10 | — | — | US | disclosed |
| US-20120010127-A1 | Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same | BERMAN JUDD M (CA) | 2012-01-12 | — | — | US | disclosed |
| US-20110098277-A1 | Fab I Inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2011-04-28 | — | — | US | disclosed |
| US-7879872-B2 | comprising (E)-N-methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide or pharmaceutically acceptable salts thereof; and gentamicin; wherein combination has an fractional inhibitory coconcentration index value of 0.3 against S. aureus 29213 | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2011-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010127-A1 | Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same | DBI, SERPINB1, CTSF | CRBN 3584/4885 |
| US-20110098277-A1 | Fab I Inhibitors | SERPINB1, TMBIM6, GDI2 | CRBN 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.